HALF-LIFE FACTOR CONCENTRATES
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
-
No change to factor IX product mix in Quebec
Montreal, August 15, 2022 – On July 15, Héma-Québec announced the results of the recombinant factor IX tender for the period from October 1, 2022...
-
Hearing the patient voice on therapy choice: FVIII or non-FVIII
by the Canadian Association of Nurses in Hemophilia Care – Ontario Region* and Sarah Crymble, Ontario Hemophilia Provincial Coordinator Treatment for patients with hemophilia A...
-
CBS supplier contracts for rFVIII and rFIX take effect April 4
March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...